KBC Group NV Cuts Stock Holdings in Humana Inc. (NYSE:HUM)

KBC Group NV reduced its position in Humana Inc. (NYSE:HUM - Free Report) by 5.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,969 shares of the insurance provider's stock after selling 2,716 shares during the quarter. KBC Group NV's holdings in Humana were worth $12,164,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. LFA Lugano Financial Advisors SA increased its position in Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock valued at $32,000 after purchasing an additional 45 shares during the period. OFI Invest Asset Management bought a new position in shares of Humana during the fourth quarter valued at approximately $33,000. Riverview Trust Co purchased a new position in Humana during the first quarter valued at approximately $34,000. Garde Capital Inc. bought a new position in Humana in the first quarter worth approximately $36,000. Finally, Transce3nd LLC purchased a new stake in Humana during the fourth quarter worth $38,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Performance

NYSE:HUM traded down $9.08 during midday trading on Wednesday, hitting $243.50. The company's stock had a trading volume of 2,586,851 shares, compared to its average volume of 1,809,719. Humana Inc. has a fifty-two week low of $212.45 and a fifty-two week high of $406.46. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.91 and a quick ratio of 1.91. The firm has a market cap of $29.39 billion, a P/E ratio of 17.22, a P/E/G ratio of 1.84 and a beta of 0.44. The firm's 50 day moving average is $241.77 and its 200-day moving average is $258.95.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, beating the consensus estimate of $10.07 by $1.51. The business had revenue of $32.11 billion for the quarter, compared to the consensus estimate of $32 billion. Humana had a net margin of 1.42% and a return on equity of 14.47%. The business's revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the prior year, the firm earned $7.23 EPS. Equities analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 annualized dividend and a dividend yield of 1.45%. Humana's dividend payout ratio (DPR) is presently 25.04%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Wall Street Zen upgraded Humana from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Guggenheim began coverage on Humana in a research note on Wednesday, April 9th. They issued a "buy" rating and a $326.00 target price on the stock. Mizuho increased their price target on shares of Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a research report on Wednesday, April 9th. Raymond James Financial upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price target on the stock in a report on Thursday, May 1st. Finally, Barclays set a $268.00 price objective on shares of Humana and gave the stock an "equal weight" rating in a research note on Thursday, June 12th. Sixteen research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $280.76.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.